Cargando…

Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries

BACKGROUND: While household contact investigation is widely recommended as a means to reduce the burden of tuberculosis (TB) among children, only 27% of eligible pediatric household contacts globally received preventive treatment in 2018. We assessed the cost-effectiveness of household contact inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Youngji, Gomes, Isabella, Flack, Joseph, Salazar-Austin, Nicole, Churchyard, Gavin, Chaisson, Richard E., Dowdy, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846666/
https://www.ncbi.nlm.nih.gov/pubmed/33554088
http://dx.doi.org/10.1016/j.eclinm.2020.100707
_version_ 1783644777275719680
author Jo, Youngji
Gomes, Isabella
Flack, Joseph
Salazar-Austin, Nicole
Churchyard, Gavin
Chaisson, Richard E.
Dowdy, David W.
author_facet Jo, Youngji
Gomes, Isabella
Flack, Joseph
Salazar-Austin, Nicole
Churchyard, Gavin
Chaisson, Richard E.
Dowdy, David W.
author_sort Jo, Youngji
collection PubMed
description BACKGROUND: While household contact investigation is widely recommended as a means to reduce the burden of tuberculosis (TB) among children, only 27% of eligible pediatric household contacts globally received preventive treatment in 2018. We assessed the cost-effectiveness of household contact investigation for TB treatment and short-course preventive therapy provision for children under 15 years old across 12 high TB burden countries. METHODS: We used decision analysis to compare the costs and estimated effectiveness of three intervention scenarios: (a) status quo (existing levels of coverage with isoniazid preventive therapy), (b) contact investigation with treatment of active TB but no additional preventive therapy, and (c) contact investigation with TB treatment and provision of short-course preventive therapy. Using country-specific demographic, epidemiological and cost data from the literature, we estimated annual costs (in 2018 USD) and the number of TB cases and deaths averted across 12 countries. Incremental cost effectiveness ratios were assessed as cost per death and per disability-adjusted life year [DALY] averted. FINDINGS: Our model estimates that contact investigation with treatment of active TB and provision of preventive therapy could be highly cost-effective compared to the status quo (ranging from $100 per DALY averted in Malawi to $1,600 in Brazil; weighted average $383 per DALY averted [uncertainty range: $248 – $1,130]) and preferred to contact investigation without preventive therapy (weighted average $751 per DALY averted [uncertainty range: $250 – $1,306]). Key drivers of cost-effectiveness were TB prevalence, sensitivity of TB diagnosis, case fatality for untreated TB, and cost of household screening. INTERPRETATION: Based on this modeling analysis of available published data, household contact investigation with provision of short-course preventive therapy for TB has a value-for-money profile that compares favorably with other interventions. FUNDING: Unitaid (2017–20-IMPAACT4TB).
format Online
Article
Text
id pubmed-7846666
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78466662021-02-04 Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries Jo, Youngji Gomes, Isabella Flack, Joseph Salazar-Austin, Nicole Churchyard, Gavin Chaisson, Richard E. Dowdy, David W. EClinicalMedicine Research Paper BACKGROUND: While household contact investigation is widely recommended as a means to reduce the burden of tuberculosis (TB) among children, only 27% of eligible pediatric household contacts globally received preventive treatment in 2018. We assessed the cost-effectiveness of household contact investigation for TB treatment and short-course preventive therapy provision for children under 15 years old across 12 high TB burden countries. METHODS: We used decision analysis to compare the costs and estimated effectiveness of three intervention scenarios: (a) status quo (existing levels of coverage with isoniazid preventive therapy), (b) contact investigation with treatment of active TB but no additional preventive therapy, and (c) contact investigation with TB treatment and provision of short-course preventive therapy. Using country-specific demographic, epidemiological and cost data from the literature, we estimated annual costs (in 2018 USD) and the number of TB cases and deaths averted across 12 countries. Incremental cost effectiveness ratios were assessed as cost per death and per disability-adjusted life year [DALY] averted. FINDINGS: Our model estimates that contact investigation with treatment of active TB and provision of preventive therapy could be highly cost-effective compared to the status quo (ranging from $100 per DALY averted in Malawi to $1,600 in Brazil; weighted average $383 per DALY averted [uncertainty range: $248 – $1,130]) and preferred to contact investigation without preventive therapy (weighted average $751 per DALY averted [uncertainty range: $250 – $1,306]). Key drivers of cost-effectiveness were TB prevalence, sensitivity of TB diagnosis, case fatality for untreated TB, and cost of household screening. INTERPRETATION: Based on this modeling analysis of available published data, household contact investigation with provision of short-course preventive therapy for TB has a value-for-money profile that compares favorably with other interventions. FUNDING: Unitaid (2017–20-IMPAACT4TB). Elsevier 2021-01-07 /pmc/articles/PMC7846666/ /pubmed/33554088 http://dx.doi.org/10.1016/j.eclinm.2020.100707 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Jo, Youngji
Gomes, Isabella
Flack, Joseph
Salazar-Austin, Nicole
Churchyard, Gavin
Chaisson, Richard E.
Dowdy, David W.
Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries
title Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries
title_full Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries
title_fullStr Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries
title_full_unstemmed Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries
title_short Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries
title_sort cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846666/
https://www.ncbi.nlm.nih.gov/pubmed/33554088
http://dx.doi.org/10.1016/j.eclinm.2020.100707
work_keys_str_mv AT joyoungji costeffectivenessofscalingupshortcoursepreventivetherapyfortuberculosisamongchildrenacross12countries
AT gomesisabella costeffectivenessofscalingupshortcoursepreventivetherapyfortuberculosisamongchildrenacross12countries
AT flackjoseph costeffectivenessofscalingupshortcoursepreventivetherapyfortuberculosisamongchildrenacross12countries
AT salazaraustinnicole costeffectivenessofscalingupshortcoursepreventivetherapyfortuberculosisamongchildrenacross12countries
AT churchyardgavin costeffectivenessofscalingupshortcoursepreventivetherapyfortuberculosisamongchildrenacross12countries
AT chaissonricharde costeffectivenessofscalingupshortcoursepreventivetherapyfortuberculosisamongchildrenacross12countries
AT dowdydavidw costeffectivenessofscalingupshortcoursepreventivetherapyfortuberculosisamongchildrenacross12countries